PCN66 Cost-Effectiveness of Denosumab Versus Zoledronic Acid for Skeletal-Related Event (SRE) Reduction in Bone-Metastatic Prostate Cancer (mPC) in the UK
Abstract
Authors
M.F. Botteman J.A. Carter P. Fishman D. Chandiwana M. Bains S.J. Snedecor